Current screening, often with high-cost diagnostics such as magnetic resonance imaging (MRI) or endoscopic ultrasonography (EUS), is limited to people with a family history of pancreatic cancer or genetic risk factors (BRCA2 mutation, Lynch syndrome, or familial adenomatous polyposis) [30]. This evidence concerns the gene BRCA2 and pancreatic neoplasm.